Clinical Report: Financial Impact of Hidradenitis Suppurativa in Spain

Overview

This study estimates the economic burden of hidradenitis suppurativa (HS) in Spain, revealing an average annual cost of €39,535.10 per patient. The findings highlight the significant societal impact of HS, driven by healthcare costs and informal caregiving.

Background

Hidradenitis suppurativa is a chronic inflammatory skin disorder that severely affects patients' quality of life and is associated with various comorbidities. With a prevalence of approximately 1% in Spain, HS often goes under-recognized, leading to delays in diagnosis and treatment. Understanding the economic burden of HS is crucial for healthcare decision-makers to prioritize health policies and allocate resources effectively.

Data Highlights

The study estimates the economic burden of HS in Spain for 2024, with costs stratified by disease severity.

Key Findings

• The average annual cost per patient with HS is €39,535.10.
• Informal caregiving expenses significantly contribute to the overall economic burden.
• HS leads to lower employment rates and increased absenteeism, impacting productivity.
• Only 10% of HS patients receive an accurate diagnosis, often leading to advanced disease stages at diagnosis.
• Healthcare costs rise with disease severity, necessitating extensive healthcare resources.

Clinical Implications

Healthcare professionals should prioritize early diagnosis and treatment of HS to mitigate its economic impact and improve patient quality of life. Understanding the financial burden can guide resource allocation and health policy formulation.

Conclusion

The economic burden of hidradenitis suppurativa in Spain underscores the need for improved recognition and management of the disease. Addressing these challenges can enhance patient outcomes and reduce societal costs.

References

1. Drugs - Real World Outcomes, Springer, 2025 -- The Financial and Societal Impact of Pulmonary Arterial Hypertension in Italy: An Analysis of Healthcare Costs
2. conexiant, HS Linked to Higher Cancer Risk
3. Updates in Surgery, Springer, 2022 -- Day Surgery for Inguinal Hernia Repair in Spain: A Population-Based Analysis of 1,163,039 Patients—Clinical and Socioeconomic Influences on Surgical Decisions
4. Elevated Incidence of Hidradenitis Suppurativa Among Individuals with Perianal Fistulas, Springer, 2019
5. Munin, European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment
6. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa - PubMed
7. Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa: A Living Systematic Review and Network Meta-Analysis | Dermatology | JAMA Dermatology | JAMA Network
8. Munin: European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment
9. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa - PubMed
10. Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa: A Living Systematic Review and Network Meta-Analysis | Dermatology | JAMA Dermatology | JAMA Network